As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
GLP-1 drugs, or GLP-1 receptor agonists, were originally solely intended for use as diabetes ... Rybelsus is currently available in a range of territories including the US, the EU, the UK, Switzerland ...
Teva Pharmaceuticals also offers a generic form of Victoza, a GLP-1 drug first approved for Type 2 diabetes in 2010. 3. Cost issues GLP-1 list prices are about $1,000 for a four-week supply ...